An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease

Adam W. ClarkeTeva Pharmaceuticals, R&D, Biologics, Lead Antibody Discovery, Sydney, AustraliaCorrespondence[email protected]

Lynn PoultonTeva Pharmaceuticals, R&D, Biologics, Lead Antibody Discovery, Sydney, Australia

Doris ShimTeva Pharmaceuticals, R&D, Biologics, Lead Antibody Discovery, Sydney, Australia

David MabonTeva Pharmaceuticals, R&D, Biologics, Lead Antibody Discovery, Sydney, Australia

Danyal ButtTeva Pharmaceuticals, R&D, Biologics, Lead Antibody Discovery, Sydney, Australia

Matthew PollardTeva Pharmaceuticals, R&D, Biologics, Lead Antibody Discovery, Sydney, Australia

Vanya PandeTeva Pharmaceuticals, R&D, Biologics, Lead Antibody Discovery, Sydney, Australia

Jean HustenTeva Pharmaceuticals, R&D, Biologics, Assays and Technology, West Chester, PA, USA

Jacquelyn LyonsTeva Pharmaceuticals, R&D, Biologics, Assays and Technology, West Chester, PA, USA

Chen TianTeva Pharmaceuticals, R&D, Biologics, Lead Antibody Discovery, Sydney, Australia

Anthony G. DoyleTeva Pharmaceuticals, R&D, Biologics, Lead Antibody Discovery, Sydney, Australia

Your download is now in progress and you may close this window